Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
887
archived clinical trials in
Autism

Functional Magnetic Resonance Imaging (fMRI) for the Study of Response Inhibition, and Face and Linguistic Processing in Autism
fMRI for the Study of Response Inhibition, and Face and Linguistic Processing in Autism
Status: Archived
Mount Sinai Hospital
2401
mi
from 98109
New York, NY
Functional Magnetic Resonance Imaging (fMRI) for the Study of Response Inhibition, and Face and Linguistic Processing in Autism
fMRI for the Study of Response Inhibition, and Face and Linguistic Processing in Autism
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
2401
mi
from 98109
New York, NY
Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders
An Investigation of the Efficacy in Childhood Obsessive-Compulsive Disorder of Riluzole: An Antiglutamatergic Agent
Status: Archived
National Institutes of Health Clinical Center
2315
mi
from 98109
Bethesda, MD
Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders
An Investigation of the Efficacy in Childhood Obsessive-Compulsive Disorder of Riluzole: An Antiglutamatergic Agent
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
2315
mi
from 98109
Bethesda, MD
Effect of Hyperbaric Therapy on Markers of Oxidative Stress in Children With Autism
Effect of Hyperbaric Therapy on Markers of Oxidative Stress in Children With Autism: A Pilot Study
Status: Archived
ICDRC
2602
mi
from 98109
Melbourne, FL
Effect of Hyperbaric Therapy on Markers of Oxidative Stress in Children With Autism
Effect of Hyperbaric Therapy on Markers of Oxidative Stress in Children With Autism: A Pilot Study
Status: Archived
Updated: 1/1/1970
ICDRC
2602
mi
from 98109
Melbourne, FL
Cognitive Behavioral Therapy for Core Autism Symptoms in School-Aged Children: A Randomized, Controlled Trial
Cognitive Behavioral Therapy for Core Autism Symptoms in School-Aged Children: A Randomized, Controlled Trial
Status: Archived
David Geffen School of Medicine, UCLA
979
mi
from 98109
Los Angeles, CA
Cognitive Behavioral Therapy for Core Autism Symptoms in School-Aged Children: A Randomized, Controlled Trial
Cognitive Behavioral Therapy for Core Autism Symptoms in School-Aged Children: A Randomized, Controlled Trial
Status: Archived
Updated: 1/1/1970
David Geffen School of Medicine, UCLA
979
mi
from 98109
Los Angeles, CA
Autism Spectrum Disorders (ASD) Characterization Study
A Characterization Study of Individuals With Autism Spectrum Disorders
Status: Archived
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Autism Spectrum Disorders (ASD) Characterization Study
A Characterization Study of Individuals With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Lincoln Medical Center
1350
mi
from 98109
Lincoln, NE
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Lincoln Medical Center
1350
mi
from 98109
Lincoln, NE
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
629
mi
from 98109
Sacramento, CA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
629
mi
from 98109
Sacramento, CA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site 021
682
mi
from 98109
San Francisco, CA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 021
682
mi
from 98109
San Francisco, CA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
2708
mi
from 98109
Boca Raton, FL
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
2708
mi
from 98109
Boca Raton, FL
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
1732
mi
from 98109
Chicago, IL
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
1732
mi
from 98109
Chicago, IL
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
University of Pittsburgh and University of Pittsburgh Medical Center
2134
mi
from 98109
Pittsburgh, PA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
University of Pittsburgh and University of Pittsburgh Medical Center
2134
mi
from 98109
Pittsburgh, PA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Sheppard Pratt Health System
2324
mi
from 98109
Baltimore, MD
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Sheppard Pratt Health System
2324
mi
from 98109
Baltimore, MD
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
2413
mi
from 98109
Manhasset, NY
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
2413
mi
from 98109
Manhasset, NY
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
2024
mi
from 98109
Cleveland, OH
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
2024
mi
from 98109
Cleveland, OH
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative
1466
mi
from 98109
Enid, OK
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative
1466
mi
from 98109
Enid, OK
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
1518
mi
from 98109
Oklahoma City, OK
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
1518
mi
from 98109
Oklahoma City, OK
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
2134
mi
from 98109
Pittsburgh, PA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
2134
mi
from 98109
Pittsburgh, PA
A Study of Oxytocin in Children and Adolescents With Autistic Disorder
A Pilot Study of Oxytocin in Children and Adolescents With Autistic Disorder
Status: Archived
University of North Carolina Chapel Hill
2335
mi
from 98109
Chapel Hill, NC
A Study of Oxytocin in Children and Adolescents With Autistic Disorder
A Pilot Study of Oxytocin in Children and Adolescents With Autistic Disorder
Status: Archived
Updated: 1/1/1970
University of North Carolina Chapel Hill
2335
mi
from 98109
Chapel Hill, NC
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Southwest Autism Research and Resource Center
1115
mi
from 98109
Phoenix, AZ
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Southwest Autism Research and Resource Center
1115
mi
from 98109
Phoenix, AZ
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
University of California, Davis Medical Center
629
mi
from 98109
Sacramento, CA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
University of California, Davis Medical Center
629
mi
from 98109
Sacramento, CA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
University of California Davis Cancer Center
628
mi
from 98109
Sacramento, CA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
628
mi
from 98109
Sacramento, CA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Pharmax Research Clinic
2727
mi
from 98109
Miami, FL
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Pharmax Research Clinic
2727
mi
from 98109
Miami, FL
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Lake Mary Pediatrics
2531
mi
from 98109
Orange City, FL
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Lake Mary Pediatrics
2531
mi
from 98109
Orange City, FL
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Institute for Behavioral Medicine
2168
mi
from 98109
Smyrna, GA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Institute for Behavioral Medicine
2168
mi
from 98109
Smyrna, GA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Institute for Juvenile Research
1732
mi
from 98109
Chicago, IL
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Institute for Juvenile Research
1732
mi
from 98109
Chicago, IL
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
James Whitcomb Riley Hospital for Children
1866
mi
from 98109
Indianapolis, IN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
James Whitcomb Riley Hospital for Children
1866
mi
from 98109
Indianapolis, IN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Kennedy Krieger Institute
2329
mi
from 98109
Baltimore, MD
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Kennedy Krieger Institute
2329
mi
from 98109
Baltimore, MD
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Umass Memorial Medical Center
2454
mi
from 98109
Worcester, MA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Umass Memorial Medical Center
2454
mi
from 98109
Worcester, MA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Univeristy of Missouri-Kansas City
1503
mi
from 98109
Kansas City, MO
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Univeristy of Missouri-Kansas City
1503
mi
from 98109
Kansas City, MO
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Seaver Autism Center, Mount Sinai Medical Center
2402
mi
from 98109
New York, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Seaver Autism Center, Mount Sinai Medical Center
2402
mi
from 98109
New York, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
New York State Institute for Basic Research in Dev. Disabilities
2399
mi
from 98109
Staten Island, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
New York State Institute for Basic Research in Dev. Disabilities
2399
mi
from 98109
Staten Island, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
University of North Carolina Hospital
2329
mi
from 98109
Chapel Hill, NC
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital
2329
mi
from 98109
Chapel Hill, NC
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Children's Hospital of Denver
1021
mi
from 98109
Denver, CO
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Children's Hospital of Denver
1021
mi
from 98109
Denver, CO
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Cutting Edge Research
1518
mi
from 98109
Oklahoma City, OK
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Cutting Edge Research
1518
mi
from 98109
Oklahoma City, OK
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Summit Research Network
146
mi
from 98109
Portland, OR
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Summit Research Network
146
mi
from 98109
Portland, OR
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Suburban Research Associates
2363
mi
from 98109
Media, PA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Suburban Research Associates
2363
mi
from 98109
Media, PA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Children's Hospital at Downstate
2407
mi
from 98109
Brooklyn, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
2407
mi
from 98109
Brooklyn, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Le Bonheur Children's Hospital
1864
mi
from 98109
Memphis, TN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Le Bonheur Children's Hospital
1864
mi
from 98109
Memphis, TN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Red Oak Psychiatry Associates, P.A.
1874
mi
from 98109
Houston, TX
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Red Oak Psychiatry Associates, P.A.
1874
mi
from 98109
Houston, TX
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Road Runner Research
1774
mi
from 98109
San Antonio, TX
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Road Runner Research
1774
mi
from 98109
San Antonio, TX
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Children's Hospital - Boston
2484
mi
from 98109
Boston, MA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
2484
mi
from 98109
Boston, MA
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
Status: Archived
University of North Carolina Hospital at Chapel Hill
2329
mi
from 98109
Chapel Hill, NC
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital at Chapel Hill
2329
mi
from 98109
Chapel Hill, NC
Social and Communication Outcomes for Young Children With Autism
Optimizing Social and Communication Outcomes for Young Children With Autism
Status: Archived
San Francisco General Hospital
683
mi
from 98109
San Francisco, CA
Social and Communication Outcomes for Young Children With Autism
Optimizing Social and Communication Outcomes for Young Children With Autism
Status: Archived
Updated: 1/1/1970
San Francisco General Hospital
683
mi
from 98109
San Francisco, CA
Social and Communication Outcomes for Young Children With Autism
Optimizing Social and Communication Outcomes for Young Children With Autism
Status: Archived
Florida State University College of Medicine
2329
mi
from 98109
Tallahassee, FL
Social and Communication Outcomes for Young Children With Autism
Optimizing Social and Communication Outcomes for Young Children With Autism
Status: Archived
Updated: 1/1/1970
Florida State University College of Medicine
2329
mi
from 98109
Tallahassee, FL
Social and Communication Outcomes for Young Children With Autism
Optimizing Social and Communication Outcomes for Young Children With Autism
Status: Archived
Kennedy Krieger Institute
2329
mi
from 98109
Baltimore, MD
Social and Communication Outcomes for Young Children With Autism
Optimizing Social and Communication Outcomes for Young Children With Autism
Status: Archived
Updated: 1/1/1970
Kennedy Krieger Institute
2329
mi
from 98109
Baltimore, MD
Social and Communication Outcomes for Young Children With Autism
Optimizing Social and Communication Outcomes for Young Children With Autism
Status: Archived
University of Michigan Health Systems
1902
mi
from 98109
Ann Arbor, MI
Social and Communication Outcomes for Young Children With Autism
Optimizing Social and Communication Outcomes for Young Children With Autism
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
1902
mi
from 98109
Ann Arbor, MI
Social and Communication Outcomes for Young Children With Autism
Optimizing Social and Communication Outcomes for Young Children With Autism
Status: Archived
University of Washington
28
mi
from 98109
Seattle, WA
Social and Communication Outcomes for Young Children With Autism
Optimizing Social and Communication Outcomes for Young Children With Autism
Status: Archived
Updated: 1/1/1970
University of Washington
28
mi
from 98109
Seattle, WA
Optimizing Social and Communication Outcomes for Toddlers With Autism
Optimizing Social and Communication Outcomes for Toddlers With Autism
Status: Archived
University of California, Irvine Medical Center
984
mi
from 98109
Orange, CA
Optimizing Social and Communication Outcomes for Toddlers With Autism
Optimizing Social and Communication Outcomes for Toddlers With Autism
Status: Archived
Updated: 1/1/1970
University of California, Irvine Medical Center
984
mi
from 98109
Orange, CA
Comprehensive Collection, Charting, and Communication System
Phase 1 Study of a Digital/Internet/Mobile System for Collecting, Charting and Communicating About the Behaviors of Children on the Autism Spectrum
Status: Archived
SymTrend
2478
mi
from 98109
Belmont, MA
Comprehensive Collection, Charting, and Communication System
Phase 1 Study of a Digital/Internet/Mobile System for Collecting, Charting and Communicating About the Behaviors of Children on the Autism Spectrum
Status: Archived
Updated: 1/1/1970
SymTrend
2478
mi
from 98109
Belmont, MA